NCT01936532 (IFM2013-06) is a Phase 2 clinical trial of MLN9708 in Newly Diagnosed Multiple Myeloma, sponsored by Nantes University Hospital.

Who is sponsoring NCT01936532?

NCT01936532 is sponsored by Nantes University Hospital.

What drugs are being tested in NCT01936532?

Interventions in NCT01936532: MLN9708, Lenalidomide, Dexamethasone.

What condition does NCT01936532 study?

NCT01936532 studies Newly Diagnosed Multiple Myeloma.

Is NCT01936532 still recruiting?

NCT01936532 is currently completed. Last updated 2 August 2023.

Last reviewed 2023-08-02 · How we verify

NCT01936532: IFM2013-06

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years

Completed Phase 2 Last updated 2 August 2023

What this trial tests

Phase 2 trial testing MLN9708 in Newly Diagnosed Multiple Myeloma in 42 participants. Completed in 4 June 2020.

Timeline

12 November 2014

Primary endpoint
1 March 2019

4 June 2020

Quick facts

Lead sponsor	Nantes University Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	12 November 2014
Primary completion	1 March 2019
Estimated completion	4 June 2020
Sites	10 locations across France

Drugs / interventions tested

MLN9708 — full drug profile →
Lenalidomide — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

Newly Diagnosed Multiple Myeloma — all drugs for Newly Diagnosed Multiple Myeloma →

Sponsor

Nantes University Hospital

Who can join

Adults 18 to 66, any sex, with Newly Diagnosed Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the stringent Complete Response (sCR) rate of the combination of MLN9708, Lenalidomide and Dexamethasone in newly diagnosed multiple myeloma (MM) patients after extended consolidation therapy
Time frame: sixteen months

Sponsor's own description

This is a phase II, multicenter, open-label study to evaluate the safety and efficacy of MLN9708 in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma. The patient population will consist of adult men and women younger than 66 years, who have a confirmed diagnosis of MM who meet eligibility criteria. Following the screening period, patients will be enrolled and treated then, they will receive induction therapy (3 cycles), a systematic Peripheral Blood Stem Cell harvest. After Peripheral Blood Stem Cell Transplantation, patient will enter in the consolidation phase (early and late one) 2 months after transplantation. Finally, patients follow a Maintenance therapy (start 1 month after the last cycle of consolidation) during 12 months.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B, Ghazarian RN, Ou M, Luderer MJ, et al · · 2016 · cited 87× · PMID 26811670 · DOI 10.2147/dddt.s93602
An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.
Offidani M, Corvatta L, Caraffa P, Gentili S, et al · · 2014 · cited 40× · PMID 25302026 · DOI 10.2147/ott.s49187
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian D, Mo CC, Landgren O, Richardson PG. · · 2020 · cited 25× · PMID 32501533 · DOI 10.1111/bjh.16764
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Sengsayadeth S, Malard F, Savani BN, Garderet L, et al · · 2017 · cited 25× · PMID 28338672 · DOI 10.1038/bcj.2017.23
Trial Watch: Proteasomal inhibitors for anticancer therapy.
Obrist F, Manic G, Kroemer G, Vitale I, et al · · 2015 · cited 17× · PMID 27308423 · DOI 10.4161/23723556.2014.974463

Verify or expand the search:

Other trials of MLN9708

Trials testing the same drug.

NCT03731832 — Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory · Phase 2 · completed
NCT02477215 — Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma · Phase 1, PHASE2 · completed
NCT02384746 — Phase I Study of the Combination of MLN9708 and Fulvestrant · Phase 1 · terminated
NCT02169791 — Nonmyeloablative Haploidentical Transplant Followed by MLN9708 · Phase 2 · completed
NCT02042989 — MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies · Phase 1 · completed

Other recruiting trials for Newly Diagnosed Multiple Myeloma

Currently open trials in the same condition.

NCT06679101 — A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab · Phase 3 · recruiting
NCT06682156 — Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients · recruiting
NCT05259553 — Biomarkers in Multiple Myeloma · NA · recruiting

Other Nantes University Hospital trials

Trials by the same sponsor.

NCT07278661 — Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery. · Phase 2 · recruiting
NCT06681363 — Creation of a Biocollection of Patients With Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelod · not yet recruiting
NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
NCT07490379 — Comparison of the Efficacy of Transcranial Direct Current Stimulation at Home Versus in Hospital Settings in Patients Wi · NA · not yet recruiting
NCT07423481 — Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01936532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nantes University Hospital
Last refreshed: 2 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01936532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing